How to Buy Arbutus Biopharma Stock
Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States.
Arbutus Biopharma stock last closed at $3.55, up 4.11% from the previous day, and has increased 30.04% in one year. It has overperformed other stocks in the Biotechnology industry by 1.07 percentage points. Arbutus Biopharma stock is currently +34.98% from its 52-week low of $2.63, and -24.87% from its 52-week high of $4.73.
As of Apr 30, 2025, there are 191.48M shares of ABUS outstanding. The market capitalization of ABUS is $679.75M. In the last 24 hours, 1.14M ABUS shares were traded.
How to Buy Arbutus Biopharma Stock
Wondering how to invest in Arbutus Biopharma stock? Here's how.
- Decide where to buy Arbutus Biopharma stock: You need to decide on a stock brokerage, but don't worry - we've researched dozens of online stock brokerages and apps to help you determine where to buy Arbutus Biopharma stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Pick your payment method and add your information.
- Analyze Arbutus Biopharma stock: The Arbutus Biopharma ticker symbol is ABUS. Is Arbutus Biopharma stock a good investment? Should you buy shares of ABUS? How do ABUS's underlying business fundamentals look? Do top analysts think Arbutus Biopharma is a good buy? Why has ABUS's stock price moved recently? (Hint: Our stock market research website can help you evaluate if ABUS is a good stock to buy).
- Execute your ABUS trade: Decide if you will purchase ABUS shares at the current market price or use a limit order to purchase ABUS stock at a particular price.
- Get key alerts regarding your ABUS position: Create a watchlist to keep tabs on your new investment in Arbutus Biopharma stock.
Step 1: Decide where to buy Arbutus Biopharma stock
You will need an online brokerage account in order to access the NASDAQ market and buy ABUS stock.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Financial Services, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal details so you can buy ABUS stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to open your new trading account.
- Submit your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've finished signing up on one of the best stock trading apps, your next step is to transfer the money for your investment:
Check out this video walkthrough if you need help transferring money into your brokerage account.
Step 4: Analyze Arbutus Biopharma stock
After you have chosen the best place to buy Arbutus Biopharma stock, it's absolutely critical to analyze their stock prior to buying, so you truly wrap your head around the risk and upside.
Arbutus Biopharma Numbers
ABUS Fundamentals
WallStreetZen was created to help part-time investors do more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on ABUS's stock page.
Is ABUS stock undervalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ABUS's intrinsic value.
Using relative valuations ratios:
- ABUS may be overvalued based on its P/B ratio of 6.98x, relative to Biotechnology industry P/B ratio of 4.45x
You can do additional valuation research on ABUS's stock here.
A quick look at ABUS Financials
Passed Financial Due Diligence Checks:
- ABUS has a low debt to equity ratio of 0.35.
- There are more short-term assets than short-term liabilities on the ABUS balance sheet.
- There are more short-term assets than long-term liabilities on the ABUS balance sheet.
- Total ABUS debt is lower than 5 years ago, relative to shareholder equity.
- ABUS has cash burn of 65032000. It has enough cash and short-term investments to cover this for at least one year.
- ABUS has $122.62M in cash and short term investments. This is enough to cover its annual cash burn of $65.03M.
Failed Financial Due Diligence Checks:
- ABUS profit margin has gone down from -401.6% to -1,133% in the past year.
Is ABUS stock a Buy, Hold, or Sell, according to analysts?
Out of 2 Equities analysts who track ABUS, the consensus analyst rating on Arbutus Biopharma is a Strong Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are projecting on the Arbutus Biopharma stock forecast page.
ABUS Trading Indicators
ABUS Performance Metrics
Last year, ABUS revenue was $6.17M. During the past five year, ABUS's revenue has gone up by 0.53% per year. This was slower than the Biotechnology industry average of 45.66%.
Find out more about ABUS's earnings and revenue performance here.
Are ABUS insiders buying or selling the stock?
Over the past 12 months, executives and large shareholders at ABUS have sold more shares than they have bought.
David C. Hastings, Chief Financial Officer of ABUS, was the latest ABUS insider to sell. They sold $72,826.79 worth of ABUS shares on Feb 4, 2025.
Get more info about who owns ABUS shares here.
Does ABUS provide a stable income stream?
No, Arbutus Biopharma doesn't provide an income stream by paying out dividends.
ABUS Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your ABUS trade
You have two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly fine for most investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, use a limit order.
Hit the Open button and your broker will place the order.
If you want additional assistance investing in stocks on eToro, watch the how to video below:
Step 6: Get key alerts regarding your ABUS position
Now that you own some ABUS shares, you'll want to keep up with your new company.
Start a watchlist to see the latest developments about your ABUS stock.
ABUS Feed
How to Buy Stock in Arbutus Biopharma
To reiterate, here are the 6 steps to buy stock in Arbutus Biopharma:
- Decide where to buy Arbutus Biopharma stock
- Open a brokerage account
- Deposit funds into your brokerage account
- Analyze Arbutus Biopharma stock
- Execute your ABUS trade
- Get key alerts regarding your ABUS position
If you require a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to track your new investment in Arbutus Biopharma, click the button below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.